Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt

NCT ID: NCT01635959

Last Updated: 2014-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3170 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Upper Gastro-intestinal Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Gastrointestinal Trackt Symptoms

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and above
* Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting.

Exclusion Criteria

* Participating on a clinical trial during the last 3 months.
* Patients not able to read and/or understand the GERD-Q questionnaire.
* Patients already included in the study in other participating site.
* Patients taking PPIs or H2blockers in the l
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dina A Ahmed, MD

Role: STUDY_DIRECTOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Al Mansurah, , Egypt

Site Status

Research Site

Al Menia, , Egypt

Site Status

Research Site

Alex, , Egypt

Site Status

Research Site

Asuit, , Egypt

Site Status

Research Site

Aswān, , Egypt

Site Status

Research Site

Banhā, , Egypt

Site Status

Research Site

Cairo, , Egypt

Site Status

Research Site

Domiaat, , Egypt

Site Status

Research Site

Hurghada, , Egypt

Site Status

Research Site

Ismailia, , Egypt

Site Status

Research Site

Kafr ash Shaykh, , Egypt

Site Status

Research Site

Kalubia, , Egypt

Site Status

Research Site

Luxor, , Egypt

Site Status

Research Site

Mahala, , Egypt

Site Status

Research Site

Menofia, , Egypt

Site Status

Research Site

Port-Saeed, , Egypt

Site Status

Research Site

Qina, , Egypt

Site Status

Research Site

Sharkiah, , Egypt

Site Status

Research Site

Sohag, , Egypt

Site Status

Research Site

Suiz, , Egypt

Site Status

Research Site

Tanta, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-GEG-XXX-2012/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Barrett's Esophagus in Patients with GERD
NCT06897540 NOT_YET_RECRUITING NA